The Food and Drug Administration has decided to delay its approval for new diabetes drug, dapagliflozin, created jointly by AstraZeneca and Bristol-Myers Squibb.  Regulators in the U.S. said that they cannot approve the experimental drug without more data. AstraZeneca and Bristol-Myers Squibb have announced that they are working with the FDA to determine their next steps and are in ongoing discussions...